CURRENT TECHNOLOGIES AND CLINICAL TRIALS IN KIDNEY TRANSPLANTATION
https://doi.org/10.15825/1995-1191-2014-3-63-75
Abstract
Since 1999 living-donor kidney transplantation (LDKT) is one of the priorities in the work of our Center. More than 45% of kidney transplants performed annually are the LDKTs. Long-term outcomes of the fi rst 357 LDKTs demonstrate good 10-year patient and graft survival: 93,5% and 73,0%, respectively. In this group we identify the risk factors of poor graft survival: age of the recipient less than 18 years, duration of dialysis before transplantation more than 24 months and creatinine level at discharge more than 130 mmol/L. The next step was the introduction of laparoscopic donor nephrectomy in clinical practice in 2009. In 2011 we start the AB0-incompatible
LDKT (iAB0) program. Effective desensitization procedure and satisfactory results of iAB0 transplants (3-year patient and graft survival: 100% and 87.5%, respectively), as well as the availability of Luminex technology allowed us to start the clinical trials in patients with pre-existing high levels of anti-HLA antibodies. In this article we both analyze our current results, and focus on topical issues requiring further research.
About the Authors
Y. G. Moysyuk
V.I. Shumakov Federal Research Center of Transplantology and Artifi cial Organs of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation
Transplantology and Artifi cial Organs Department, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation
Russian Federation
Russian Federation
Head of Liver and Kidney transplantation Division V.I. Shumakov Federal Research Center of Transplantology and Artifi cial Organs, Moscow, Russian Federation; professor of Chair of Transplantology and Artifi cial organs I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.
A. I. Sushkov
V.I. Shumakov Federal Research Center of Transplantology and Artifi cial Organs of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation
Russian Federation
Russian Federation
Research Fellow in Clinical Transplantation Department at the same center
A. V. Sharshatkin
V.I. Shumakov Federal Research Center of Transplantology and Artifi cial Organs of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation
Russian Federation
Russian Federation
Leading Research Fellow in Clinical Transplantation Department
at the same center
B. T. Bikbov
V.I. Shumakov Federal Research Center of Transplantology and Artifi cial Organs of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation
Nephrology Department, A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russian Federation
Moscow City Nephrology Center, Moscow City Hospital № 52, Moscow, Russian Federation
Russian Federation
Russian Federation
Senior Research Fellow in Clinical Transplantation Department at the same center; Assistant Professor Nephrology Department, A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russian Federation; nephrologist Moscow City Nephrology Center, Moscow City Hospital № 52, Moscow, Russian Federation
O. V. Azarenkova
V.I. Shumakov Federal Research Center of Transplantology and Artifi cial Organs of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation
Russian Federation
nephrologist in Kidney and Liver Transplantation Unit at the same center
Russian Federation
nephrologist in Kidney and Liver Transplantation Unit at the same center
References
1. Jordan SC, Pescovitz MD. Presensitization: the problem and its management. Clin J Am Soc Nephrol. 2006 May; 1 (3): 421–432.
2. Meier-Kriesche H, Port FK, Ojo AO, Leichtman AB, Rudich SM, Arndorfer JA et al. Deleterious effect of waiting time on renal transplant outcome. Transplant Proc. 2001 Feb-Mar; 33 (1–2): 1204–1206.
3. Weimert NA, Allo way RR. Renal transplantation in highrisk patients. Drugs. 2007; 67 (11): 1603–1627.
4. Готье СВ, Мойсюк ЯГ, Хомяков СМ. Донорство и трансплантация органов в Российской Федерации в 2013 году. VI сообщение регистра Российского трансплантологического общества. Вестник трансплантологии и искусственных органов. 2014; XVI (2): 5–29. Gautier SV, Moĭ syuk YaG, Khomyakov SM. Donorstvo i transplantatsiya organov v Rossiĭ skoĭ Federatsii v 2013 godu. VI soobshchenie registra Rossiĭ skogo transplantologicheskogo obshchestva. Vestnik ransplantologii i iskusstvennykh organov = Russian Journal of Transplantology and Artifi cial Organs. 2014; XVI (2): 5–29.
5. Mengel M, Husain S , Hidalgo L, Sis B. Phenotypes of antibody-mediated rejection in organ transplants. Transpl Int. 2012 Jun; 25 (6): 611–622.
6. Montgomery RA, Lonz e BE, King KE, Kraus ES, Kucirka LM, Locke JE et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med. 2011 Jul 28; 365 (4): 318–326.
7. Tyden G, Kumlien G, Fehrman I. Successful AB0-incompatible kidney transplantations without splenectomy using antigen-specifi c immunoadsorption and rituximab. Transplantation. 2003 Aug 27; 76 (4): 730–731.
8. Сушков АИ, Шаршаткин АВ, Азаренкова ОВ, Ефимкин АС, Малахов АГ, Сайдулаев ДА и др. Преодоление барьера несовместимости по группе крови при трансплантации почки от родственного донора. Нефрология и диализ. 2013; 15 (4): 286–292. Sushkov AI, Sharshatkin AV, Azarenkova OV, Efi mkin AS, Malakhov AG, Saĭ dulaev DA et al. Preodolenie bar'era esovmestimosti po gruppe krovi pri transplantatsii pochki ot rodstvennogo donora. Nefrologiya i dializ. 2013; 15 (4): 286–292.
9. Jordan SC, Reinsmoen N , Peng A, Lai CH, Cao K, Villicana R et al. Advances in diagnosing and managing antibody-mediated rejection. Pediatr Nephrol. 2010 Oct; 25 (10): 2035–4205; quiz 45–48.
Review
For citations:
Moysyuk Y.G., Sushkov A.I., Sharshatkin A.V., Bikbov B.T., Azarenkova O.V. CURRENT TECHNOLOGIES AND CLINICAL TRIALS IN KIDNEY TRANSPLANTATION. Russian Journal of Transplantology and Artificial Organs. 2014;16(3):63-75. (In Russ.) https://doi.org/10.15825/1995-1191-2014-3-63-75
Views:
2379
Email this article 